These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 9084456

  • 1. Bromfenac disposition in patients with impaired kidney function.
    Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM.
    Clin Pharmacol Ther; 1997 Mar; 61(3):312-8. PubMed ID: 9084456
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of bromfenac in healthy subjects after single oral administration of three different doses.
    Högger P, Rohdewald P.
    Arzneimittelforschung; 1993 Oct; 43(10):1114-8. PubMed ID: 8267679
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB, Baughman S, Sullivan JT.
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL.
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R.
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A, Ventura D, Rao N, Abramowitz W.
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [Abstract] [Full Text] [Related]

  • 12. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery.
    Forbes JA, Sandberg RA, Bood-Björklund L.
    Pharmacotherapy; 1998 Jan; 18(3):492-503. PubMed ID: 9620100
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers.
    Högger P, Rohdewald P.
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):377-85. PubMed ID: 10475140
    [Abstract] [Full Text] [Related]

  • 17. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F, Floridi AG, Floridi A, Buoncristiani U.
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S, Borgå O, Edenius C, Jostell KG, Odergren T, Weil A.
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [Abstract] [Full Text] [Related]

  • 19. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C, Bagnis C, Mamet JP, Peck RW, Deray G.
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of aspoxicillin in subjects with normal and impaired renal function.
    Geyer J, Höffler D, Koeppe P.
    Arzneimittelforschung; 1988 Nov; 38(11):1635-9. PubMed ID: 3214450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.